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A B S T R A C T
The Bcl-2 protein has been shown to suppress cell death and protects cell against apoptosis induced by different
death-inducing signals. In this study the authors have analyzed imunohistochemically the expression of Bcl-2 protein in
the histopathological variants of the most common malignant tumors of the skin – basal cell carcinoma (BCC) and
squamous cell tumor (SCC), as well as in the precancerous lesion actinic keratosis (AK) and in benign tumor seborrheic
keratosis (SK). Bcl-2 expression in solid, adenoid and cystic variants of BCC exhibited immunoreactivity of tumor stroma
with more intense staining among peripheral palisading cells. Morphoeic variant demonstrated reduced amount of Bcl-2
expression. Among SCC in all samples, tumor tissue lack to express Bcl-2 positivity. In cases of hypertrophic and atro-
phic variants of AK, Bcl-2 expression was confined to basal cell layer, as well as in one case of hypertrophic variant in
suprabasal cells. In three histological variants of SK expresseion of Bcl-2 protein was in areas of basaloid proliferation,
while in areas of squamous differentiation was negative. In clonal variant immunostaining was positive among cells in
characteristic »nests« Distribution of Bcl-2 protein expression in solid, adenoid and cystic variant of BCC showed that
peripheral proliferating cells are protected against apoptosis what permits tumor growth. In morpheaform variant re-
duced amount of Bcl-2 expression indicated that this variant of BCC has increased cell proliferation, and in practice
shows tendency for recurrence and difficulties to eradicate. Bcl-2 expression supports the observation that tumor cells are
derived from basal keratinocytes. In SCC, lack of Bcl-2 expression indicates that origin of tumor cells is from more differ-
entiated suprabasal keratinocytes. In AK results suggest that immunoreactivity is regulated with respect of the kerati-
nocyte’s differentiation status, but not closely correlate with proliferative rate.
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Introduction
A fundamental feature of carcinogenesis is deregula-
tion of normal cellular genes termed proto-oncogenes.
The products of activated proto-oncogenes and mutated
tumor suppressor-genes act to cause increased cellular
proliferation. They contribute to malignancy by inhibit-
ing programmed cell death. In the cell death pathway,
bcl-2 is the best understood gene, and it functions as a
repressor of programmed cell death1–3.
The cell cycle, which includes cellular proliferation
pathways, is regulated by multiple genes. Some of them
are oncogenes which have been divided into two catego-
ries: genes that promote cellular proliferation and growth,
and genes that regulate apoptosis2,3. Apoptosis is a type
of cell death that has been shown to differ from necrosis
by well defined ultrastructural and biochemical criteria.
bcl-2 is among the most widely studied of those onco-
genes known as regulators of apoptotic cell death4. Bcl-2
protein is a suppressor of the cell death. It protects a cell
against apoptosis induced by different death-inducing
signals. So, Bcl-2 expression in tumor or proliferating tis-
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sue can predict behavior, prognosis and therapeutic re-
sults4–8. In the normal mature human skin, Bcl-2 expres-
sion is limited to cells within the basal layer of epidermis,
as well as within melanocytes, outer root sheath, dermal
papillae of hair follicles, epithelial cells of the secretory
coils of eccrine sweat glands and in the excretory ducts of
sebaceous glands but not in the suprabasal cell layers of
the epidermis5,9–11. It is possible that Bcl-2 positive cells
appear to serve as reserve cells from which squamous ep-
ithelium renews itself11. Bcl-2 expression may be impor-
tant for the maintenance of stem cells compartments in
tissues that undergo continuous self-renewal5,12–14. Bcl-2
protein is localized on the mitochondrial inner mem-
brane and suppresses apoptotic mode of cell death6,7.
Basal cell carcinoma (BCC) and squamous cell carci-
noma (SCC) of the skin are the most common neoplasms
which originate from epidermal keratinocytes. Both pre-
dominantly develop on sun-exposed sites, either as a re-
sult of UV induced DNA damage or UV-induced immuno-
suppression12–15. BCCs are slow growing tumors taking
months to years to reach significant proportions16. Sev-
eral explanations for this behavior have been proposed
as; tumoral prolongation of the S-phase of the cell cycle;
a small proportion of proliferating cells; tumor regres-
sion in response to host immune factors; enzyme lysis of
adjacent connective tissue and mechanical resistance of
the dermis counteracting the expansion of the carcino-
ma17. Several histopathological variants exist; solid, ade-
noid, cystic and morphoeic17. As BCC is thought to arise
from basal keratinocytes, Bcl-2 expression is expected in
BCC tumor cells.
In SCC, which originate from suprabasal keratino-
cytes, would be expected to be negative for Bcl-2, as well
as in actinic keratosis (AK) whose cells also originate
from suprabasal cell layers2. According to histopatholo-
gical variants, there are hypertrophic, atrophic, acantho-
lytic and bowenoid form17. Seborrheic keratosis (SK) is
by far one of the most common benign skin tumors in the
dermatological practice. It consists of localized prolifera-
tion of basaloid keratinocytes with subsequently papillo-
matosis and pseudocysts appearance1.
The aim of this study was to examine in details the
distribution of Bcl-2 protein within the normal skin in-
cluding the epidermis and adnexal structures and com-
pare with distribution in the most frequent histopatholo-
gical variants of BCC, SCC, AK and SK. The aim was also
to evaluate the potential histogenetic origin of particular
groups of cells in various variants of these tumors and
precancerous lesions.
Materials and Methods
Surgical specimens were obtained from the Outpa-
tient Department Clinical Hospital Center Split. The
specimens included: five solid variants of BCC, five ade-
noid, five cystic and five morpheaform variants of BCC.
Among SCC, 10 samples were of the first grade, and ten
of second grade according to Broders. Five hypertrophic
and five atrophic variants of actinic keratosis and five
acanthotic types, five irritated and five clonal variants of
seborrheic keratosis were examined. The samples with
minimal pigmentation and contents of melanin were cho-
sen in order to avoid positive results because of melano-
cyte Bcl-2 expression.
The control group contained ten specimens of normal
photoexposed skin obtained from dorsal skin of hands.
The diagnosis was established on 5 mm thickness
hematoxylin-eosin (HE) stained sections. For immuno-
histochemistry the paraffin sections were deparaffinized
by placing them through two 10-minute changes of xylene,
and then dehydrated in absolute ethanol. Endogenous
peroxidase was blocked with 3% hydrogen peroxide in
distilled water for 5 minutes. Slides were rehydrated in
decreasing concentrations of ethanol, and rinsed in dis-
tilled water. To optimize Bcl-2 detection, sections were
placed in a thermoresistant jars in citrate buffer, pH 6,
and exposed for 10 minutes to microwave fixation at 750
W until boiling to increase immunoreactivity. The slides
were removed from oven and left to cool for 20 minutes
until room temperature was reached. Slides were then
washed in distilled water and in phosphate-buffered sa-
line solution. The specimens were incubated at room
temperature for another 30 minutes with monoclonal an-
tibody Bcl-2 at a dilution of 1:500 (M887 DAKO, Glo-
strup, Denmark). They were then rinsed with phos-
phate-buffered saline and incubated with
biotin-conjugated goat anti-mouse IgG at a dilution of
1:400 for 40 minutes. A biotin-streptavidin detection sys-
tem was employed with diaminobenzidine (DAB) (Sigma,
Borneum, Belgium) as the chromogen. The slides were
rinsed repeatedly with phosphate buffered saline and in-
cubated with biotinylated rabbit antimouse immuno-
globulin for 30 minutes, and again rinsed with phos-
phate-buffered saline, and then incubated in 0.5% copper
sulfate and lightly counterstained with hematoxylin.
Basal cells and scattered lymphocytes within dermal
infiltrates, both of which normally expressed Bcl-2, as
well as normal skin sections, served as positive internal
controls. Negative controls were sections with omission
of the primary antibody, or incubated with an irrelevant
antibody.
Results
All specimens were assessed for Bcl-2 expression by
immunohistochemical staining. A fine granular brown
cytoplasmatic staining of the cells with Bcl-2 was consid-
ered positive. In the epidermis of normal photoexposed
skin in 10 samples, Bcl-2 expression was uniformly pres-
ent in the basal cell layer. Epithelial cells in the infun-
dibulum of the hair follicles, cells lining the ducts of seba-
ceous glands, sebaceous glands and eccrine sweat ducts
also showed expression of Bcl-2. The suprabasal layers
were consistently negative. Positive expression was found
within melanocyte and some cellular components of der-
mal infiltrate as it was within lymphocytes, plasma cells
and endothelial cells (Figure 1).
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All variants of BCCs were Bcl-2 positive with homoge-
neous cytoplasmatic staining throughout the whole le-
sion, but much more prominent on the periphery of the
solid, adenoid and cystic variants (Figures 2–4). Mor-
pheaform variant showed reduced amount of Bcl-2 ex-
pression (Figure 5). In all samples of SCCs no one ex-
pressed bcl-2 (Figure 6). In specimens of hypertrophic
and atrophic variants of AK, Bcl-2 expression was con-
fined to basal cell layer, as well as in one case of hypertro-
phic form in suprabasal cells (Figure 7). Five samples of
acanthotic and irritated variant of SK revealed positive
staining for Bcl-2 expression (Figure 8). The areas of
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Fig. 1. Immunohistochemical staining with anti-bcl-2 monoclo-
nal antibody of normal photoexposed skin (´ 40).
Fig. 2. Immunohistochemical staining with anti-bcl-2 monoclonal
antibody of solid variant of basal cell carcinoma (´ 40).
Fig. 3. Immunohistochemical staining with anti-bcl-2 monoclonal
antibody of adenoid variant of basal cell carcinoma (´ 100).
Fig. 4. Immunohistochemical staining with anti-bcl-2 monoclonal
antibody of cystic variant of basal cell carcinoma (´ 40).
Fig. 5. Immunohistochemical staining with anti-bcl-2 monoclonal
antibody of morpheaform variant of basal cell carcinoma (´ 40).
Fig. 6. Immunohistochemical staining with anti-bcl-2 monoclonal
antibody of well differentiated squamous cell carcinoma (´ 40).
squamous differentiation lacked Bcl-2 expression partic-
ularly in irritated variant of SK (Figure 9). Examination
of five clonal variants revealed positive immunostaining
with anti-bcl-2 within basaloid keratinocytes as well as
within characteristic »nests« (Figure 10).
Discussion and Conclusion
The physiologic role of Bcl-2 protein is to prevent or
delay programmed cell death during proliferation. The
distribution of the Bcl-2 in normal photoexposed skin
suggests that expression is limited exclusively to the
basal cell layer which has been committed to the forma-
tion of the epidermis and adnexal structures5. Investiga-
tion of Bcl-2 expression revealed that it is not strictly cor-
related with proliferative rate of keratinocyte but more
closely correlates with the differentiation status of the
cell. This is possible reason why immunoreactivity is not
found in suprabasal and upper layers of epidermis5,8–10.
These cells of the basal layer which is the major proli-
ferative compartment, express Bcl-2 that may function
in protecting of basal cells from the death after apoptotic
stimuli. Consistent with this role, cells whose major
function to give rise to new cell populations are Bcl-2 pos-
itive. Suprabasal keratinocytes with subsequent rising to
upper parts of epidermis can undergo either apoptosis or
much more often terminal differentiation depending upon
balance of regulatory factors, intrinsic and external fac-
tors11,15. Nakagawa’s results are not consistent with these
results probably due to the different antibodies and tech-
nique used in studies6. In this investigation we examined
three variations of seborrheic keratosis. The most com-
mon type is acanthotic. Irritaded type can be found on
photoexposed areas or after irritation with chemicals.
Pesce and Scalora propose that apoptosis has a role in the
squamous differentiation in irritated SK16. Their results
supported hypothesis that in irritated type of SK is de-
creased binding of epidermal growth factor. They postu-
lated that this variant can correspond with involution
phase of the lesion characterized by an altered cell ba-
lance16. On the other side, Ackerman proposed that in
this type of SK, squamous eddies represent tangential
section of spirals of sebaceous and eccrine ducts through
the acanthotic epidermal proliferation17. Comparing this
statement with findings of Bcl-2 immunoreactivity of the
excretory duct of sebaceal and eccrine glands, we must
N. Puizina-Ivi} et al.: Bcl-2 Expression, Coll. Antropol. 32 (2008) Suppl. 2: 61–65
64
Fig. 7. Immunohistochemical staining with anti-bcl-2 monoclonal
antibody of hypertrophic variant of actinic keratosis (´ 40).
Fig. 8. Immunohistochemical staining with anti-bcl-2 monoclonal
antibody of acanthotic variant of seborrhoic keratosis (´ 100).
Fig. 9. Immunohistochemical staining with anti-bcl-2 monoclonal
antibody of irritated variant of seborrhoic keratosis (´ 100).
Fig. 10. Immunohistochemical staining with anti-bcl-2 monoclonal
antibody of clonal variant of seborrhoic keratosis (´ 40).
point out that this statement must be changed. This
findng gives a new light in the field of histogenesis of this
variant of SK. The fact that in clonal variant of SK,
basaloid keratinocytes and cells within »nests« are Bcl-2
positive as well as within excretory ducts of sebaceal and
eccrine glands in the control normal skin, can indicate
that this variant of SK can represent tangential section
of excretory ducts of adnexal epitehlium through epi-
deral proliferation. Further investigations are necessary
to be performed maybe with some novel antibodies in or-
der to resolve this dilemma.
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PREGLED IZRA@AJANOSTI Bcl-2 BJELAN^EVINE U HISTOPATOLO[KIM VARIJANTAMA
BAZOCELULARNOG I PLANOCELULARNOG KARCINOMA TE AKTINI^KE I SEBOROJI^NE
KERATOZE
S A @ E T A K
Pokazalo se da Bcl-2 bjelan~evina suprimira stani~nu smrt i tako {titi stanice od apoptoze koja je inducirana razli-
~itim signalima. U ~lanku, autori prou~avaju imunohistokemijsku izra`ajnost Bcl-2 bjelan~evine u histopatolo{kim va-
rijantama naj~e{}ih malignih tumora ko`e – bazocelularnom karcinomu (BCC) i planocelularnom karcinomu (SCC), te
u prekanceroznoj leziji aktino~ke keratoze (AK) te dobro}udnom tumoru – seboroi~noj bradavici (SK). Izra`ajnost Bcl-2
u solidnoj, adenoidnoj i cisti~noj varijanti BCC pokazala se u stromi tumora sa ne{to ja~om obojano{}u perifernih pali-
sadnih slojeva tumora. Morfeiformna varijanta pokazala je slabiju imunorekativnost na anti-Bcl-2. Svi uzorci SCC nisu
pokazali reaktivnost na anti-Bcl-2 monoklonsko bojanje. U slu~aju hipertrofi~ne i atrofi~ne varijante AK, Bcl-2 izra`aj-
nost je vi|ena samo u bazalnom sloju, dok je u samo jednom uzorku hipertrofi~ne varijante vi|ena i suprabazalno. U sve
tri varijante SK izra`ajnost Bcl-2 bjelan~evine je bila ograni~ena na podru~ja sa bazaloidnom proliferacijom, dok je u
podru~jima sa ro`natom diferencijacijom bila negativna. U klonalnoj varijnati, imunohistokemijski pozitivitet je doka-
zan unutar karakteristi~nih »gnijezda«. Izra`ajnost Bcl-2 bjelan~evine u solidnoj, adenoidnoj i cisti~noj varijnati BCC,
pokazuje da je rubni sloj stanica za{ti}en od apoptoze {to omogu}ava rast tumora. U morfeiformnoj varijanti smanjena
izra`ajnost Bcl-2 ukazuje da ova varijanta ima ubrzanu stani~nu proliferaciju te u praksi pokazuje sklonost recidivima
uz ote`ano iskorjenjivanje. Bcl-2 izra`ajnost potvr|uje da su tumorske stanice nastale iz bazalnoig sloja. U SCC, manjak
izra`ajnosti Bcl-2 ukazuje ja je podrijeklo tumoskih stanica iz bolje diferenciranih suprabazalnih keratinocita. U akti-
ni~koj keratozi rezultati ukazuju da je imunoreaktivnost odre|ena stupnjem diferencijacije keratoinocita, ali nije usko
povezana sa stupnjem proliferacije.
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